OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis $0.05 +0.00 (+2.12%) As of 09/23/2026 03:43 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PVCT alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0652-Week Range$0.04▼$0.09Volume58,440 shsAverage Volume164,465 shsMarket Capitalization$22.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing investigational medicines for cancer and other serious diseases. The company’s principal technology is based on rose bengal, a small-molecule compound that has been studied for potential therapeutic applications. Provectus’s lead product candidate, PV-10, is an investigational intralesional treatment designed to be injected directly into tumors. The company has evaluated PV-10 in clinical studies involving melanoma and other solid tumors, including research into whether treatment of an injected lesion may stimulate an immune response against cancer cells elsewhere in the body. PV-10 is not an approved treatment and remains subject to clinical and regulatory evaluation. The company has also investigated PH-10, a topical formulation of rose bengal intended for dermatological conditions. Provectus has historically conducted or supported development activities in the United States and other regions, including Australia. Its programs have remained in the research and clinical-development stage, and the company’s publicly available information may change as it evaluates financing, regulatory, and development strategies.AI Generated. May Contain Errors. Read More Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVCT Stock News HeadlinesVisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company ShowcaseJuly 22, 2026 | globenewswire.comIndependent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same DoseJuly 7, 2026 | globenewswire.comWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing.September 24 at 1:00 AM | The Oxford Club (Ad)Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular InfectionsJune 30, 2026 | globenewswire.comProvectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)June 25, 2026 | globenewswire.comProvectus Shareholders Approve Reverse Stock Split AuthorityJune 22, 2026 | tipranks.comProvectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call TranscriptJune 18, 2026 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of StockholdersJune 8, 2026 | globenewswire.comSee More Headlines PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed this year? Provectus Biopharmaceuticals' stock was trading at $0.0550 on January 1st, 2026. Since then, PVCT shares have decreased by 3.8% and is now trading at $0.0529. How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), American Superconductor (AMSC), Company Calendar Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year Founded2002Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.43 million Net MarginsN/A Pretax Margin-9,731.04% Return on EquityN/A Return on Assets-599.37% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual Sales$340 thousand Price / Sales65.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-2.65Miscellaneous Outstanding Shares420,280,000Free Float335,383,000Market Cap$22.23 million OptionableNot Optionable Beta0.86 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:PVCT) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
